Frank Gannon

Nessuna posizione attualmente

Consumer Services

Health Technology

Profilo

Frank Gannon is the founder of Elara Pharmaceuticals GmbH, which was founded in 2006.
He held the title of Mitgründer from 2006 to 2009.
Dr. Gannon's former jobs include Executive Director at the European Molecular Biology Organization in 2007 and Senior Scientist at The European Molecular Biology Laboratory from 1994 to 2007.
Dr. Gannon received a doctorate degree from the University of Leicester in 1973.

Precedenti posizioni note di Frank Gannon

Società	Posizione	Fine
European Molecular Biology Organization	Direttore/Membro del Consiglio	01/01/2007
The European Molecular Biology Laboratory	Corporate Officer/Principal	01/01/2007
Elara Pharmaceuticals GmbH Elara Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany.	Fondatore	-

Vedi nel dettaglio l'esperienza di Frank Gannon

Formazione di Frank Gannon

University of Leicester

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Frank Gannon

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Elara Pharmaceuticals GmbH Elara Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany.	Health Technology
European Molecular Biology Organization